Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.

Although C max showed a trend to slightly decrease under fed conditions (C max‐fed /C max‐fasted : 0.801; 90% CI, 0.638–1.01), a slight increase in AUC last (AUC last‐fed /AUC last‐fasted : 1.30; 90% CI, 1.14–1.47) was observed (Table S2 ).

also in 53,322 other papers